What this test measures
Lp(a) is a low-density lipoprotein-like particle with an additional apolipoprotein(a) attached. Its plasma concentration is 80–90% genetically determined (LPA gene polymorphisms), stable across life, and largely unaffected by diet, exercise, or statins. Lp(a) is independently atherogenic (promotes both atherosclerosis and thrombosis) and now widely recognised as a major hereditary CV risk factor.
Why it matters
ESC/EAS 2019 explicitly recommends measuring Lp(a) at LEAST ONCE in every adult, as it identifies a substantial slice of inherited CV risk that conventional lipid profile misses. About 20% of the global population has Lp(a) > 50 mg/dL — and that group has 2–3 fold higher MI, stroke, aortic stenosis, and PAD risk. Indian data suggest Lp(a) is even more prevalent at high levels, contributing to South Asians' excess premature CV disease. Currently no specific Lp(a)-lowering drug is licensed (apheresis in extreme cases; PCSK9 inhibitors lower by 25–30%; antisense / siRNA drugs in trials). Awareness of high Lp(a) motivates aggressive control of all OTHER risk factors (LDL, BP, diabetes).
How to prepare
No fasting required. Single measurement is usually adequate — Lp(a) is stable lifelong. Disclose any current PCSK9 inhibitor (lowers Lp(a) ~25%), niacin (lowers ~20%), and recent acute infection / inflammation (transiently raises).
Markers & reference ranges
Reference ranges below are typical adult values. Your lab's reported range may differ slightly based on the assay platform and patient demographics — always read your report against the range printed on it.
| Marker | Normal range | If low | If high |
|---|---|---|---|
| Lipoprotein(a) (mg/dL or nmol/L (note: nmol/L is preferred — assay-dependent))[1][2] | Optimal < 30 mg/dL (< 75 nmol/L); Risk threshold ≥ 50 mg/dL (≥ 125 nmol/L) | < 30 mg/dL: low CV risk contribution from Lp(a). | 30 – 50 mg/dL: borderline. ≥ 50 mg/dL (≥ 125 nmol/L): high — independent CV risk 2-3x higher; intensify management of OTHER modifiable risk factors (LDL, BP, smoking, diabetes); consider PCSK9 inhibitor if also FH. ≥ 100 mg/dL: very high — strongly motivate primary prevention; consider apheresis if recurrent events. |
Lp(a) risk bands
| Lp(a) mg/dL | Lp(a) nmol/L | CV risk | Action |
|---|---|---|---|
| < 30 | < 75 | Low | Standard prevention |
| 30 – 50 | 75 – 125 | Borderline | Aggressive LDL / BP control |
| 50 – 100 | 125 – 250 | High | Aggressive LDL / BP; consider PCSK9-i |
| > 100 | > 250 | Very high | Aggressive control; consider apheresis if recurrent events |
Frequently asked questions
Why test only once?
Lp(a) is 80-90% genetically determined and stable lifelong — repeat testing rarely changes management. ESC/EAS recommends one-off measurement in every adult to identify hereditary risk.
Can I lower Lp(a) with diet or exercise?
Mostly no — diet and exercise have minimal effect. Niacin lowers ~20%, PCSK9 inhibitors ~25-30%, and lipoprotein apheresis can dramatically lower it for very-high-risk cases. Specific Lp(a)-lowering drugs (olpasiran, pelacarsen) are in late-phase trials.
My Lp(a) is high — what do I do?
High Lp(a) cannot easily be lowered, so the strategy is to compensate by aggressively controlling all other modifiable risk factors: low LDL target, BP control, no smoking, treat diabetes, healthy weight. Tell first-degree relatives to also get tested (it is hereditary).
Are mg/dL and nmol/L interchangeable?
No — they measure different things (mass vs molar particle number) and the conversion factor varies by Lp(a) isoform. The trend in guidelines is to report nmol/L; some labs convert using ~2.5 ratio but this is approximate. Use the same unit consistently.
Do statins lower Lp(a)?
No — statins do NOT lower Lp(a) and may even raise it slightly. This is why measuring Lp(a) once is important — it identifies risk that statins won't address.
Should family members be tested?
Yes — Lp(a) is heritable; first-degree relatives of someone with high Lp(a) should also be tested, especially if there is family history of premature CV disease.
Related Lipids / Cardiac Risk tests
Tests commonly ordered alongside LIPOPROTEIN (A) [LP(A)], or that help interpret an unexpected result.
Sources & references
- ESC/EAS 2019 Dyslipidaemia Guideline · accessed 2026-05-30T00:00:00.000Z
- AHA Scientific Statement on Lp(a) · accessed 2026-05-30T00:00:00.000Z
- Lipid Association of India · accessed 2026-05-30T00:00:00.000Z
- NIH MedlinePlus — Lipoprotein(a) · accessed 2026-05-30T00:00:00.000Z
Book with Zelnoo
Get your LIPOPROTEIN (A) [LP(A)] test done at home — transparent prices, NABL-accredited labs.
Zelnoo lets you compare diagnostic test prices across NABL-accredited labs in Mumbai & Thane, book a free home phlebotomist visit, and receive digital reports in 24–48 hours into a consent-first report vault. No subscriptions, no membership fees — pay only for the test you book.
Book LIPOPROTEIN (A) [LP(A)] now